Objective:To identify the impact on asthma by the treatment of mometasone furoate monohydrate nasal spray to allergic rhinitis.Methods:This was an opened own control study.25 patients with asthma and rhinitis were given inhaled-powder salmeterol/fluticasone50 μg/250 μg(Seretide)

one inhalation each time

twice daily via Diskhaler for 3 months.then added the use of mometasone furoate monohydrate nasal spray(Nasonex) 50 μg

one spray each nasal side each time

twice daily.To determine the efficacy of different treatment methods.The forced expiratory volume in one second(FEV1)

the forced vital capacity(FVC)

asthma symptom scores

nocturnal-awakening times and the amount of use of inhaled short-actingβ2-adrenoceptor agonist bronchodilators were observed respectively before the treatment

after the treatment of salmeterol/fluticasone 50 μg/250 μg for 3 months

and after the treatment of inhaled-powder salmeterol/fluticasone combined with Nasonex for 3 months.Results:The treatment of inhaled-powder salmeterol/fluticasone combined with mometasone furoate monohydrate nasal spray improved FEV1

FVC and clinical asthma symptoms

and decreased the amount of the use of inhaled short-actingβ2-adrenoceptor agonist bronchodilators

there were significant differences(P<0.05).Conclusion:The treatment to allergic rhinitis by mometasone furoate monohydrate nasal spray improved the efficacy of the treatment to asthma.